Results 11 to 20 of about 14,145 (218)
Meningococcal vaccine evolution
Clinical Management Issues, 2012 Neisseria meningitidis is a leading cause of bacterial sepsis and meningitis worldwide. Although polysaccharide and glycoconjugate vaccines have been developed for serogroups A, C, Y and W-135, currently there are no broadly effective vaccines available ...
Gianni Bona, Carla Guidi
doaj +5 more sources
Meningococcal vaccination in pregnancy [PDF]
Human Vaccines & Immunotherapeutics, 2018 Invasive meningococcal disease causes meningitis and septicemia worldwide with highest rates of disease occurring in children
Bahaa Abu Raya, Manish Sadarangani
doaj +4 more sources
Vaccines against Meningococcal Diseases [PDF]
Microorganisms, 2020 Neisseria meningitidis is the main cause of meningitis and sepsis, potentially life-threatening conditions. Thanks to advancements in vaccine development, vaccines are now available for five out of six meningococcal disease-causing serogroups (A, B, C, W,
Mariagrazia Pizza +2 more
doaj +3 more sources
Meningococcal Vaccines: Challenges and Prospects. [PDF]
Vaccines (Basel), 2020 Neisseria meningitidis is a gram-negative bacterium that causes a severe acute infection, called the meningococcal disease [...]
Bagwe P +5 more
europepmc +7 more sources
Pediatric Drugs, 2004 Meningococcal disease is one of the most feared and serious infections in the young and its prevention by vaccination is an important goal. The high degree of antigenic variability of the organism makes the meningococcus a challenging target for vaccine prevention. Meningococcal polysaccharide vaccines against serogroup A and C are efficacious and have
Rüggeberg, J, Pollard, A
openaire +6 more sources
Meningococcal Vaccinations [PDF]
Infectious Diseases and Therapy, 2016 Neisseria meningitidis, a gram-negative diplococcal bacterium, is a common asymptomatic nasopharyngeal colonizer that may infrequently lead to invasive disease in the form of meningitis or bacteremia. Six serogroups (A, B, C, W, X and Y) are responsible for the majority of invasive infections.
Eva Sullivan, Nancy F. Crum-Cianflone
openaire +2 more sources
Meningococcal Vaccine Trials [PDF]
, 2003 The evaluation of meningococcal vaccines in humans is a challenging task. Issues of safety, and benefit to the individual patient and to the community may raise difficult ethical problems. The inherent variability of human responses, the rarity of clinical disease, age-dependence in the immune response, and the role of carriers complicates the ...
Paddy Farrington, Elizabeth Miller
openalex +4 more sources
Expert Review of Vaccines, 2002 The successful introduction of a protein-polysaccharide conjugate vaccine against serogroup C meningococci into the UK infant immunization schedule, in combination with a catch-up campaign for individuals less than 18 years of age, has seen virtually all group C disease eliminated in childhood.
Bethell, D, Pollard, A
openaire +5 more sources
Meningococcal glycoconjugate vaccines [PDF]
Human Vaccines, 2011 Neisseria meningitidis is a major cause of invasive bacterial infections worldwide. For this reason, efforts to control the disease have been directed at optimizing meningococcal vaccines and implementing appropriate vaccination policies. In the past, plain polysaccharide vaccines containing purified capsular polysaccharides A, C, Y and W135 were ...
GASPARINI, ROBERTO, PANATTO, DONATELLA
openaire +3 more sources